Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Resolor meets constipation endpoint

Movetis (Vosselaar, Belgium) said oral Resolor prucalopride met the primary endpoint of the proportion

Read the full 141 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE